Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISCT 2020 | ISCT 2020: looking forward to advances and emerging technologies in immune-mediated cancer therapy

Bruce Levine • 28 May 2020
ISCT 2020
General

Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, highlights the presentations being covered in the ‘Advances and emerging technologies in immune-mediated cancer treatments’ session at the International Society for Cellular Therapy (ISCT) 2020 meeting.
This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Bruce Levine

1:26
The impact of COVID-19 on CAR-T therapy
Bruce Levine • 28 May 2020
1:15
CAR-T therapy: where is it going?
Bruce Levine • 28 May 2020
1:20
ISCT 2020: Moving ahead at full speed session - what can delegates look forward to?
Bruce Levine • 28 May 2020
1:29
Translation from academia to industry: manufacturing of CAR T-cells
Bruce Levine • 30 Jan 2020

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
3:29
PTCy as GvHD prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals